Austedo XR (deutetrabenazine extended release) / Teva - LARVOL DELTA

HDSA 2026: Austedo’s benefits extend beyond chorea treatment (Huntington’s Disease News) - "Therefore, the Huntington Study Group, a research organization, conducted a real-world, online study involving 192 adult Huntington’s patients and 233 of their caregivers to evaluate the burden of chorea on daily activities, as well as the perceived efficacy of Austedo or Austedo XR treatment...Before treatment, up to 84% of Huntington’s patients said chorea caused social or emotional disruptions or interfered with their participation in work and other everyday activities...After treatment, about three-quarters of patients reported a reduction in chorea severity, and 60% or more said they experienced improvements in social and emotional well-being and participation in everyday activities....After the person they care for started Austedo or Austedo XR, over 78% of caregivers reported improvements in these areas."

Real-world • CNS Disorders • Huntington's Disease

Assessment of Dose Proportionality and the Effect of Food on a Once-Daily Extended-Release Tablet Formulation of Deutetrabenazine in Healthy Participants. (PubMed, Clin Drug Investig) - "The once-daily formulation of deutetrabenazine exhibited dosage strength proportional pharmacokinetics for doses up to 48 mg and there was no observed effect of food."

Journal • CNS Disorders • Huntington's Disease • Movement Disorders

Teva Presents New Data on AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea (Teva Press Release) - "Across the real-world survey population, patients reported HD chorea often interfered with social life (71-84%), emotional wellbeing (68-77%), daily activities (70-78%) and vocational/recreational life (67-82%). Caregivers also reported substantial impact across their own social functioning (73–84%), emotional wellbeing (71–84%), daily activities (81–83%) and vocational/recreational life (76-83%) due to their caregiving responsibilities....As a result of movement reduction, over 85% of surveyed patients reported improvements in goals related to daily activities, such as dressing, walking and eating, and goals related to their social lives, such as going out with friends and family."

Clinical data • Real-world • CNS Disorders • Huntington's Disease

Real-world Persistence in Patients with Tardive Dyskinesia: A Comparative Study of Valbenazine and Deutetrabenazine XR (AAN 2026) - "Objective Evaluate persistence outcomes among matched deutetrabenazine-extended-release (XR) and valbenazine cohorts. Higher persistence rates with valbenazine were seen after the first month and were sustained through the 6-month follow-up. Future studies may investigate potential reasons for differences in persistence, such as titration difficulty, clinical effectiveness, and tolerability."

Clinical • Real-world • Real-world evidence • CNS Disorders • Huntington's Disease • Movement Disorders

Patient Experience With Once-daily Deutetrabenazine Extended-release Tablets for the Treatment of Tardive Dyskinesia in Individuals With Prior Valbenazine Use (AAN 2026) - "91% (PVU) and 89% (de novo) reported satisfaction with deutetrabenazine QD. Conclusions Most participants with TD who reported previously using valbenazine and those who initiated deutetrabenazine QD de novo reported improvements in their extra movements and overall satisfaction with deutetrabenazine QD."

Clinical • Genetic Disorders • Huntington's Disease • Movement Disorders

Medicare announces price cuts for…prescription drugs… (MSN News) - "Here are the negotiated prices for the drugs, based on a 30-day supply, compared to the 2024 list price:...(i) Otezla, a psoriatic arthritis drug: $1,650, down from $4,722...; (ii) Austedo and Austedo XR, for Huntington’s disease: $4,093, down from $6,623."

Commercial • Huntington's Disease • Psoriatic Arthritis

Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington's disease. (PubMed, Expert Rev Neurother) - "Due to the lack of comparative clinical trial data, no evidence-based recommendation about choice of VMAT2 inhibitor or switching between VMAT2 inhibitors can be made about best practice. Ultimately, QD dosing may offer the chance of improved medication adherence, an important consideration in patients with complex treatment regimens and/or patients with cognitive decline."

Journal • Review • ADHD (Impulsive Aggression) • Huntington's Disease • Movement Disorders

Teva Announces AUSTEDO XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day) (Businesswire) - "Teva Pharmaceuticals...today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO XR as a one pill, once-daily treatment option, now with four new tablet strengths (30, 36, 42, 48 mg) indicated in adults for TD and HD chorea."

FDA approval • CNS Disorders • Huntington's Disease

AUSTEDO XR: Clinical Considerations Across a Patient’s Journey with TD (APA 2023) - "Supported by TEVA"

Clinical

AUSTEDO XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO, Now Available in the U.S. (Businesswire) - "Teva Pharmaceuticals...today announced that once-daily AUSTEDO XR (deutetrabenazine) extended-release tablets are now available for adults in the United States in 6 mg, 12 mg and 24 mg tablet strengths. AUSTEDO XR was recently approved by the U.S. Food and Drug Administration (FDA) for adults living with tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). AUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor with 3-year data that is indicated in adults for both TD and HD chorea indications....Approximately 90% of patients with insurance coverage are expected to pay $10 or less with financial assistance offerings."

Commercial • Launch US • Genetic Disorders • Huntington's Disease

"$TEVA AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S. https://t.co/9VQrBzOXxR" (,@stock_titan)

Teva to Present New Data on Once-Daily AUSTEDO XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting (Businesswire) - "Teva Pharmaceuticals...today announced six poster abstracts across its neurology portfolio will be presented at the American Academy of Neurology (AAN) Annual Meeting on April 22-27, 2023. Abstracts include data for AUSTEDO (deutetrabenazine) tablets, as well as once-daily AUSTEDO XR (deutetrabenazine) extended-release tablets....Additional abstracts from the Enroll-HD Global Registry and AJOVY® (fremanezumab-vfrm) will also be presented."

Clinical data • Observational data • Real-world effectiveness • CNS Disorders • Genetic Disorders • Huntington's Disease • Migraine • Pain